Agent for treating keratoconjunctival trouble

Abstract

An object of the present invention is to search a new medicinal use of 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione and 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione. 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione or a salt thereof exerts an excellent improving effect on corneal disorder models, therefore, it is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis.

Description

technical field [0001] The present invention relates to containing thiazolidinedione derivative 5-[to-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione, 5-[[4 Dry eye, corneal ulcer, keratitis, A therapeutic agent for keratoconjunctivopathy such as conjunctivitis. Background technique [0002] It is known that the cornea is a transparent avascular tissue with a diameter of about 1 cm and a thickness of about 1 mm. The conjunctiva is the mucous membrane that covers the surface of the eyeball behind the limbus and the inside of the eyelids. The cornea or conjunctiva has an important impact on visual function. If corneal ulcer, keratitis, conjunctivitis, dry eye and other diseases cause keratoconjunctival lesions to be repaired delayed for some reason or protracted without repair, the cornea and conjunctiva are connected tissues, which will damage the epithelium. Normal structures are adversely affected and damage the structure or function of the corneal parenchy...

AI Technical Summary

Problems solved by technology

[0004] However, there is no research report on the pharmacological effects of the above-mentioned compounds on eye diseases such as keratoconjunctivopathy

Images